Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism

Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism

(2019) Minoru Satoh et al.   HYPERTENSION RESEARCH

Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study

(2019) Sadayoshi Ito et al.   JOURNAL OF HUMAN HYPERTENSION

Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria

(2019) Sadayoshi Ito et al.   Clinical Journal of the American Society of Nephrology

Renal impairment is closely associated with plasma aldosterone concentration in patients with primary aldosteronism

(2019) Akiyuki Kawashima et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study

(2019) Hiroshi Itoh et al.   HYPERTENSION RESEARCH

Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)

(2019) Sadayoshi Ito et al.   HYPERTENSION

Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects

(2018) Manabu Kato et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Prevalence of Cardiovascular Disease and Its Risk Factors in Primary AldosteronismNovelty and Significance

(2018) Youichi Ohno et al.   HYPERTENSION

Effect of Eplerenone on the Glomerular Filtration Rate (GFR) in Primary Aldosteronism: Sequential Changes in the GFR During Preoperative Eplerenone Treatment to Subsequent Adrenalectomy

(2018) Yujiro Nakano et al.   INTERNAL MEDICINE

Significance of Computed Tomography and Serum Potassium in Predicting Subtype Diagnosis of Primary Aldosteronism

(2017) Hironobu Umakoshi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort

(2017) Tracy A Williams et al.   Lancet Diabetes & Endocrinology

Renal Resistive Index Predicts Postoperative Blood Pressure Outcome in Primary Aldosteronism

(2016) Yoshitsugu Iwakura et al.   HYPERTENSION

The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline

(2016) John W. Funder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium

(2016) George C. Roush et al.   JOURNAL OF HYPERTENSION

CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats

(2015) Kiyoshi Arai et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Comparison of eplerenone and spironolactone for the treatment of primary aldosteronism

(2015) Shigehiro Karashima et al.   HYPERTENSION RESEARCH

Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone

(2015) Mitja Lainscak et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

(2015) Bryan Williams et al.   LANCET

Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: Systematic review and meta-analysis

(2014) Francesco Pelliccia et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Cardiovascular Complications Associated With Primary Aldosteronism

(2013) Sébastien Savard et al.   HYPERTENSION

Nifedipine controlled-release 40 mg b.i.d. in Japanese patients with essential hypertension who responded insufficiently to nifedipine controlled-release 40 mg q.d.: a phase III, randomized, double-blind and parallel-group study

(2013) Kazuaki Shimamoto et al.   HYPERTENSION RESEARCH

Long-Term Cardio- and Cerebrovascular Events in Patients With Primary Aldosteronism

(2013) Paolo Mulatero et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Mineralocorticoid receptor antagonists: their use and differentiation in Japan

(2012) Atsuhisa Sato   HYPERTENSION RESEARCH

Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension

(2012) GianLuca Colussi et al.   JOURNAL OF HYPERTENSION

Guidelines for the diagnosis and treatment of primary aldosteronism -The Japan Endocrine Society 2009-

(2011) Tetsuo Nishikawa et al.   ENDOCRINE JOURNAL

Addition of Spironolactone in Patients With Resistant Arterial Hypertension (ASPIRANT)

(2011) Jan Václavík et al.   HYPERTENSION

A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism

(2011) Hari K Parthasarathy et al.   JOURNAL OF HYPERTENSION

Cardiovascular and Cerebrovascular Comorbidities of Hypokalemic and Normokalemic Primary Aldosteronism: Results of the German Conn’s Registry

(2009) E. Born-Frontsberg et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism

(2008) Asterios Karagiannis et al.   EXPERT OPINION ON PHARMACOTHERAPY